Angina News and Research RSS Feed - Angina News and Research

Angina is chest pain or discomfort that occurs when an area of your heart muscle doesn't get enough oxygen-rich blood. Angina may feel like pressure or squeezing in your chest. The pain also may occur in your shoulders, arms, neck, jaw, or back. It can feel like indigestion.
Young women veterans referred for cardiac tests more likely to be depressed than men veterans

Young women veterans referred for cardiac tests more likely to be depressed than men veterans

Women veterans who had specialized heart tests were younger and more likely to be obese, depressed and suffer from post-traumatic stress disorder than men veterans, according to a study published in an American Heart Association journal. [More]
Eli Lilly accepts committee recommendation to extend evacetrapib Phase 3 trial

Eli Lilly accepts committee recommendation to extend evacetrapib Phase 3 trial

Eli Lilly and Company has accepted the recommendation of the ACCELERATE study academic executive committee, based on emerging science in the cardiovascular field, to extend the Phase 3 trial of the investigational medicine evacetrapib by approximately six months. [More]
CryoLife's revenues increase 5% to $37.2M in fourth quarter 2014

CryoLife's revenues increase 5% to $37.2M in fourth quarter 2014

CryoLife, Inc., a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today its results for the fourth quarter and full year of 2014. [More]
Young women report greater stress than men after heart attack

Young women report greater stress than men after heart attack

Young and middle-aged women experience more stress than their male counterparts, which could contribute to worse recovery from acute myocardial infarction (AMI), according to new findings by Yale School of Medicine researchers and their colleagues. [More]
Study assessing efficacy of Neovasc Reducer for treatment of Refractory Angina published in NEJM

Study assessing efficacy of Neovasc Reducer for treatment of Refractory Angina published in NEJM

Neovasc Inc. today announced that the final results from its COSIRA study assessing the efficacy and safety of the Neovasc Reducer for treatment of Refractory Angina, were published today in the New England Journal of Medicine. [More]
Neovasc closes underwritten public offering of common stock

Neovasc closes underwritten public offering of common stock

Neovasc Inc. is pleased to announce the closing of its previously announced underwritten public offering of 12,075,000 common shares of the Company at a price per share of US$7.19 (the "Offering") for aggregate gross proceeds of approximately US$74,883,850 for the Company and US$11,935,400 for the Selling Securityholders (as defined below) before deducting underwriting discounts and commissions and offering expenses payable by the Company and the Selling Securityholders. [More]
Study finds no evidence that testosterone replacement therapy increases cardiovascular risk

Study finds no evidence that testosterone replacement therapy increases cardiovascular risk

Fears of a link between testosterone replacement therapy and cardiovascular risk are misplaced, according to a review published in this month's Mayo Clinic Proceedings. The therapy has come under widespread scrutiny in recent months, including by a federal Food and Drug Administration panel convened last fall. [More]
Study: Poor psychosocial work environment linked to cardiovascular problems

Study: Poor psychosocial work environment linked to cardiovascular problems

A psychosocially poor work environment means that employees experience highly demanding requirements but have little ability to control their work or not feel sufficiently appreciated for the contributions they make. [More]
Cimetidine drug could be one of many common over-the-counter medicines to treat cancer

Cimetidine drug could be one of many common over-the-counter medicines to treat cancer

A popular indigestion medication can increase survival in colorectal cancer, according to research published in ecancermedicalscience. But in fact, scientists have studied this for years - and a group of cancer advocates want to know why this research isn't more widely used. [More]
Scientists identify defects in colossal heart protein which leads to stroke, heart failure

Scientists identify defects in colossal heart protein which leads to stroke, heart failure

The landmark discovery of a tiny defect in a vital heart protein has for the first time enabled heart specialists to accurately pinpoint a therapeutic target for future efforts in developing a drug-based cure for cardiovascular diseases. [More]
Using cardiac biomarkers to identify NSTEMI and ACS patients: an interview with Peter Mason

Using cardiac biomarkers to identify NSTEMI and ACS patients: an interview with Peter Mason

ACS is currently identified through the use of ECGs pre-hospital and the confirmed via a Troponin biomarker test once in the acute setting. [More]
Studies evaluate traditional management of heart attack patients after discharge from hospital

Studies evaluate traditional management of heart attack patients after discharge from hospital

Beta-blockers have been a cornerstone in the treatment of heart attack survivors for more than a quarter of a century. However, many of the data predate contemporary medical therapy such as reperfusion, statins, and antiplatelet agents, and recent data have called the role of beta-blockers into question. [More]
Women delay seeking medical care for heart symptoms, put health at risk

Women delay seeking medical care for heart symptoms, put health at risk

When heart symptoms strike, men and women go through similar stages of pain but women are more likely to delay seeking care and can put their health at risk, according to a study presented at the Canadian Cardiovascular Congress. [More]
Neovasc gets conditional IDE approval from FDA to initiate trial for Tiara mitral valve system

Neovasc gets conditional IDE approval from FDA to initiate trial for Tiara mitral valve system

Neovasc Inc. today announced that it has received conditional Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration to initiate the U.S. arm of its TIARA-I Early Feasibility Trial for the Company's Tiaraâ„¢ transcatheter mitral valve. [More]
Ferring Pharmaceuticals to introduce new cranberry flavor option of PREPOPIK in 2015

Ferring Pharmaceuticals to introduce new cranberry flavor option of PREPOPIK in 2015

Colonoscopy is an important and widely used screening tool for colorectal cancer, but for many patients the bowel-preparation process is more uncomfortable than the procedure itself. To offer an alternative choice in bowel preparation, Ferring Pharmaceuticals Inc. will introduce a new cranberry flavor option of PREPOPIK in January 2015. [More]
South Asians in Canada have higher rate of heart disease compared with white people

South Asians in Canada have higher rate of heart disease compared with white people

South Asians living in Canada have a higher rate of heart disease and double the rate of diabetes compared with while people, McMaster researchers have found. [More]
Abbott announces initiation of ABSORB IV heart stent clinical trial

Abbott announces initiation of ABSORB IV heart stent clinical trial

Abbott announced today the start of the ABSORB IV clinical trial, which will test whether its Absorb Bioresorbable Vascular Scaffold (BVS) is more cost-effective and offers a higher quality of life than a best-in-class, permanent, metallic drug eluting stent. [More]
Amgen announces phase 3 ivabradine data for treatment of chronic HF

Amgen announces phase 3 ivabradine data for treatment of chronic HF

Amgen (NASDAQ: AMGN) today announced data from the Phase 3 SHIFT (Systolic Heart failure treatment with the If inhibitor ivabradine Trial) study evaluating ivabradine in patients with chronic heart failure (HF) were presented at the 18th Annual Scientific Meeting of the Heart Failure Society of America (HFSA) in Las Vegas. [More]
Intensive glycaemic control shows ischaemic heart disease benefit

Intensive glycaemic control shows ischaemic heart disease benefit

Intensive glucose lowering may significantly reduce the risk of ischaemic heart disease in at-risk middle-aged people with Type 2 diabetes, a post-hoc analysis of the ACCORD trial suggests. [More]

FFR guided drug-eluting stenting reduces death compared to medical therapy in stable CAD patients

Fractional flow reserve (FFR)-guided drug-eluting stenting reduces death, myocardial infarction or urgent revascularisation, as compared to medical therapy in patients with stable coronary artery disease (CAD), according to the results of the FAME 2 trial presented for the first time today at ESC Congress by principal investigator Dr Bernard De Bruyne (Belgium). [More]